市場調查報告書
商品編碼
1439903
數位吸入器 - 全球市場考量、競爭格局、市場預測 (2030)Digital Dose Inhalers - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
預計 2024 年至 2030 年預測期內,全球數位吸入器市場規模將以 11.27% 的複合年增長率成長。 由於氣喘、慢性阻塞性肺病(COPD)、囊性纖維化和氣喘-COPD重疊症候群等呼吸系統疾病盛行率上升等因素,該市場呈現顯著的市場成長。 此外,領先製藥公司快速採用數位技術、空氣污染加劇、吸菸者數量增加以及接觸灰塵、煙霧和空氣顆粒的增加將推動數位吸入器市場的發展。 此外,預計近期產品發佈和監管批准等技術進步將在預測期內(2024-2030 年)推動整個數位吸入器市場的發展。 因此,預計在 2024 年至 2030 年的預測期內,市場將以顯著的複合年增長率成長。
數位吸入器市場動態
推動數位吸入器市場的關鍵特徵之一是各種呼吸系統疾病的全球盛行率不斷上升。
例如,根據世界衛生組織 (WHO) (2022) 的數據,氣喘在 2019 年影響了近 2.62 億人,同年導致全球 4.55 億人死亡。
根據全球疾病負擔研究(2019)的數據,全球慢性阻塞性肺病患者人數據報告為2.123億,2019年有330萬人死亡。我是。 除了氣喘和慢性阻塞性肺病之外,囊性纖維化的病例也在增加。 根據 March of Dimes Organization(2019 年)的數據,2019 年全球約有 70,000 至 100,000 人受到囊性纖維化的影響,男性和女性的患病率相同。
此外,預計空氣污染的加劇也將推動未來幾年對數位吸入器的需求。 例如,根據經濟合作暨發展組織(2022 年)的數據,到 2050 年,全球溫室氣體 (GHG) 排放量預計將增加約 50%,這主要是由於與能源相關的二氧化碳排放量。70%。 此外,到 2050 年,大氣中溫室氣體濃度可能達到 685 ppm CO2 當量,導致本世紀末全球平均氣溫比工業化前水平上升 3 到 6 攝氏度。我是。
除上述因素外,技術的發展不斷加快,推動了數位吸入器市場的成長。 例如,2022 年 2 月,藥物輸送系統、服務和活性材料科學解決方案的全球領導者 Aptar Pharma 宣佈推出一款創新數位設備,可將標準計量吸入器 (pMDI) 轉變為智慧互聯醫療設備。我們宣佈推出HeroTracker®Sense,一種呼吸健康解決方案。
因此,上述因素將在 2024-2030 年預測期內推動整個數位吸入器市場的發展。
然而,設備的高成本以及對數位資料準確性的擔憂可能會對數位吸入器市場的成長構成挑戰。
由於封鎖、邊境關閉等原因,COVID-19 大流行減緩了數位吸入器市場最初幾個月的成長,導致數位吸入器市場的製造、供應、進出口和其他相關活動中斷。它產生了輕微的負面影響。 此外,由於擔心 SARS-CoV-2(COVID-19 的病原體)的傳播以及大流行的不確定性,世界上許多國家已停止進行肺功能測試(PFT)(除非緊急情況)。房間被迫關閉。 然而,患有中度至重度氣喘或氣喘不受控制的人更有可能因 COVID-19 住院。 由於世界各地人們對肺部健康的認識和擔憂,Covid-19大流行也導致了下半年數位吸入器的成長,這進一步導致了用於肺功能的數位或智慧吸入器等數位吸入器的成長測試.加速吸入器的使用並推動數位吸入器市場的成長。 此外,數位吸入器電子商務的推出增加了市場需求。 因此,除了上述因素外,高疫苗接種率、政府放鬆封鎖以及對數位吸入器的需求將在2022-2028年預測期內推動整個數位吸入器市場的發展。
本報告研究和分析了全球數位吸入器市場,提供市場規模和預測、驅動因素和挑戰、公司和產品概況等。
DIGITAL DOSE INHALERS MARKET BY PRODUCT TYPE (DRY POWDER INHALERS AND METERED DOSE INHALERS), BY APPLICATION (CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, AND OTHERS), AND BY GEOGRAPHY IS EXPECTED TO ADVANCE AT A RESPECTABLE CAGR FORECAST till 2030 OWING TO THE ACCELERATING PREVALENCE OF RESPIRATORY DISORDERS SUCH AS ASTHMA, COPD, AND OTHERS, THE RISING AIR POLLUTION, AND THE GROWING NUMBER OF PRODUCT DEVELOPMENT ACTIVITIES SUCH AS PRODUCT LAUNCHES AND REGULATORY APPROVALS ACROSS THE GLOBE
The global digital dose inhalers market will grow at a CAGR of 11.27% during the forecast period from 2024 to 2030. The digital dose inhalers market is witnessing significant market growth due to the factors such as the rising prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others. Furthermore, the surging adoption of digital technology by key pharmaceutical players, the rising air pollution, increase in the population of smokers, and increasing exposure to dust, fumes, and airborne particles will spur the market of digital dose inhalers. Additionally, the growing technological advancements such as recent product launches and regulatory approvals is expected to drive the overall market for digital dose inhalers during the forecast period (2024-2030). Therefore, the market for digital dose inhalers is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.
DIGITAL DOSE INHALERS MARKET DYNAMICS:
One of the key aspect for driving the digital dose inhalers market is the rising prevalence of various respiratory disorders globally.
For instance, as per data by the World Health Organization (WHO) 2022, asthma affected approximately nearly 262 million people in 2019, causing 455,000 deaths in the same year, globally.
Also, according to data by the Global Burden of Disease Study (2019), there were 212.3 million prevalent cases of COPD reported globally, accounting for 3.3 million deaths in the year 2019. In addition to asthma and COPD, the numbers for cystic fibrosis are constantly on the rise. As per data by the March of Dimes Organization (2019), about 70,000 to 100,000 people had cystic fibrosis in the year 2019 globally, affecting males and females at the same rate.
Moreover, the rising air pollution is also expected to drive the demand for digital dose inhalers in the upcoming years. For instance, as per the Organization for Economic Co-operation and Development 2022, by 2050 the emission of global greenhouse gases (GHGs) could be anticipated to increase by about 50%, majorly owing to 70% growth in energy-related CO2 emissions. It also stated that the atmospheric concentration of GHGs could reach 685 parts per million (ppm) CO2- equivalents by 2050, resulting in the global average temperatures to be 3 to 6 degree Celsius above the pre-industrial levels by the end of the century.
Along with the factors mentioned above, the number of technological developments are constantly increasing, bolstering the growth of the digital dose inhalers market. For instance, in February 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced the launch of HeroTracker® Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device.
Therefore, the factors stated above collectively will drive the overall digital dose inhalers market during the forecast period from 2024-2030.
However, high cost of the devices, concerns regarding the accuracy of digital data, and others may prove to be challenging factors for digital dose inhalers market growth.
The COVID- 19 pandemic had a slightly negative impact on the market growth of digital dose inhalers during the initial few months owing to the lockdown impositions, border closures, and others leading to disruption in the manufacturing, supply, import, export, and other related activities of the digital dose inhalers market. Also, owing to the fear of spread of SARS-CoV-2 virus which is the causative agent for COVID-19 and uncertainties revolving around the pandemic, many countries across the world were forced to close down pulmonary function tests (PFT) laboratories except in case of emergencies. However, people suffering from moderate-to-severe or uncontrolled asthma were more likely to get hospitalized from COVID-19. The COVID -19 pandemic also led to rise in digital dose inhalers in the later half owing to the awareness and concerns regarding lung health among the people across the world which is further accelerated the utilization of respiratory inhalers such as digital or smart inhalers for the testing of lung function, driving the market growth for digital dose inhalers. Moreover, with the commencement of e-commerce availability of digital dose inhalers, increased its demand in the market. Thus, along with the above-mentioned factors, high vaccination rates and relaxations in the government-imposed lockdown, the demand for digital dose inhalers is subjected to increase driving the overall market for digital dose inhalers during the forecast period of 2022 - 2028.
DIGITAL DOSE INHALERS MARKET SEGMENT ANALYSIS:
Digital Dose Inhalers Market by Product Type (Dry Powder Inhalers and Metered Dose Inhalers), Application (Chronic Obstructive Pulmonary Disease, Asthma, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product type segment of the digital dose inhalers market, the dry powder inhalers segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the increasing prevalence of respiratory diseases, increasing technological advancements pertaining to the device, and surging launches by the key players in the market.
For instance, dry powder inhalers (DPI's) in general are easier to use than the metered dose inhalers (MDI) and cause fewer irritant effects.
Moreover, concerns related to the incidences of drug irritation caused by the presence of propellant components, such as chlorofluorocarbons (CFCs) in metered dose inhalers, have favored the adoption of the dry powder inhalers, with fewer irritant effects while delivering comparable therapeutic efficacy as metered dose inhalers. Thus, the dry powder inhalers are also known as propellant free inhalers.
Further, the DPI deposit the medicine in the lungs at a much higher rate than MDIs. This makes them more efficient and effective as they can provide a higher quantity of medicine with a single dose.
Additionally, the increasing product launches are also expected to contribute to the growth of the studied segment during the forecast period. For instance, in December 2020, Berry Global launched the RS01 single-dose dry powder inhaler with built-in sensors and digital capabilities. The RS01 tracks inhaler use and connects to a companion app that provides personalized guidance to improve adherence and inhaler technique.
Therefore, owing to the advantages associated with dry powder inhaler and increasing product launches, the category is expected to witness a considerable growth eventually contributing to the overall growth of the global digital dose inhalers market during the forecast period.
NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL DIGITAL DOSE INHALERS MARKET:
Among all the regions, North America is expected to dominate the global digital dose inhalers market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This can be ascribed to the escalating prevalence of various respiratory disorders, increasing burden of geriatric population prone to respiratory disorder, and the presence of key market players in the region are another factors which acts as a supportive factor for the North America's digital dose inhalers market growth.
As per the data published by World Health Organization (WHO) 2022, approximately 25 million people in the United States had asthma in the year 2020 including 4.2 million children, which equals about 1 in every 13 people.
Moreover, according to the National Center for Health Statistics 2019-2020, stated that the percentage of COPD, emphysema, or chronic bronchitis for adults aged 18 and over, in the United States, increased from 4.6% in 2019 to 5.0% in 2020.
In other countries of North America such as Canada, the numbers for respiratory ailments are substantially increasing. According to statistics by the Lung Association 2020-2022, it was concluded that about 2.6 million Canadians were living with asthma in the year 2020 - 2022.
Thus, from the above sources and statistics it can be concluded that the respiratory disorders are increasing in the North America, ultimately increasing the demand of digital dose inhalers in the market.
Additionally, as per the New Mexico Department of Health Epidemiology and Response Division, 2019, in the year 2023, approximately 16.0% of adults were current smokers and nearly 32.7% of high school students were current smokers. The increasing consumption of smoking will increase the risk of developing respiratory disorders or lung cancer, ultimately increasing the demand of digital dose inhalers in order to treat and manage the respiratory disorders.
Furthermore, the increasing product launches, regulatory approvals, acquisitions, partnerships, and other activities by key players in the region will drive the market of digital dose inhalers in the upcoming years. For instance, in July 2020, Teva Pharmaceuticals, one of the prominent player in healthcare industries, announced the launch of its ProAir Digihaler in the United States. It is used in people >=4 years old to treat or prevent bronchospasm in people who have reversible obstructive airway disease or to prevent exercise-induced bronchospasm.
Henceforth, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the digital dose inhalers market.
DIGITAL DOSE INHALERS MARKET KEY PLAYERS:
Some of the key market players operating in the digital dose inhalers market includes Glenmark Pharmaceuticals, Novartis AG, ResMed, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., H&T Presspart Manufacturing Ltd., AptarGroup, Inc., Amiko Digital Health Limited., Trudell Medical UK Limited, BreatheSuite Inc., Opko Health, Inc., Cipla Inc., Sensirion AG, 3M, adherium, and others.
RECENT DEVELOPMENTAL ACTIVITIES IN DIGITAL DOSE INHALERS MARKET:
In February 2022 Astrazeneca and Honeywell partnered to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less global warming potential than propellants currently used in respiratory medicines.
In February 2019, Propeller Health, delivering one of the digital respiratory health platform, signed a partnership with Orion Corporation in order to bring the Propeller's products among European patients.
KEY TAKEAWAYS FROM THE DIGITAL DOSE INHALERS MARKET REPORT STUDY
TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS DIGITAL DOSE INHALERS MARKET REPORT STUDY
FREQUENTLY ASKED QUESTIONS FOR DIGITAL DOSE INHALERS MARKET:
The digital dose inhalers are devices that deliver a specific amount of medication to the lungs in the form of aerosolized medicine or dry powder. These inhalers have built-in sensors that detect use of inhaler and measure respiratory flow, according to the release and dose management.
The global digital dose inhalers market will grow at a CAGR of 11.27% during the forecast period from 2024 to 2030.
The digital dose inhalers market is witnessing a positive market growth owing to the factors such as increasing of prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others. Further, the surge in the adoption of digital technology by key pharmaceutical players, rising air pollution, and increase in the population of smokers will aid in driving the market of digital dose inhalers. Also, the increasing product launches and regulatory approvals will create an exigency for the digital dose inhalers market.
Some of the key market players operating in the digital dose inhalers market includes Glenmark Pharmaceuticals, Novartis AG, ResMed, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., H&T Presspart Manufacturing Ltd., AptarGroup, Inc., Amiko Digital Health Limited., Trudell Medical UK Limited, BreatheSuite Inc., Opko Health, Inc., Cipla Inc., Sensirion AG, 3M, adherium, and others.
Among all the regions, North America is estimated to amass the significant revenue share in the global digital dose inhalers market. This can be ascribed to the escalating prevalence of various respiratory disorders, increasing burden of geriatric population prone to respiratory disorder, and the presence of key market players in the region are another factors which acts as a supportive factor for the North America's digital dose inhalers market growth.